Table 2.
Allogeneic HSCT.
Probability of overall survival (OS), relapse free survival (RFS), relapse incidence (RI), and non-relapse mortality (NRM) after HSCT depending on center specific economic factors.
Numbers represent hazard ratios (HR), adjusted for all other risk factors by stratification (see Methods section for details).
| OS | RFS | RI | NRM | |
|---|---|---|---|---|
| Accreditation | ||||
| JACIE − | 1 | 1 | 1 | 1 |
| JACIE + | 0·93 [0.87–0.99] | 0·95 [0.90–1.00] | 1·00 [0.93–1·06] | 0·91 [0·83–0·99] |
| Center patient volume | ||||
| Per 10 patients | 0·87 [0·84–0·91] | 0·92 [0·88–0·96] | 0·98 [0·92–1·04] | 0·86 [0·82–0·91] |
| 0–4 patients | 1 | 1 | 1 | 1 |
| 5–9 patients | 0·90 | 0·93 | 0·96 | 0·90 |
| 10–14 patients | 0·86 | 0·91 | 0·94 | 0·88 |
| 15–19 patients | 0·84 | 0·90 | 0·97 | 0·84 |
| > 20 patients | 0·78 | 0·86 | 0·95 | 0·76 |
| Center program duration | ||||
| Per 10 years | 0·90 [0·85–0·90] | 0·92 [0·87–0·96] | 0·93 [0·88–0·99] | 0·90 [0·83–0·97] |
| 0–4 years | 0·91 | 0·93 | 0·88 | 0·97 |
| 5–9 years | 0·87 | 0·89 | 0·88 | 0·90 |
| 10–14 years | 0·84 | 0·86 | 0·82 | 0·90 |
| 15–19 years | 0·81 | 0·83 | 0·85 | 0·81 |
| EBMT risk score | ||||
| Per score point | 1·21 [1·19–1·23] | 1·18 [1·16–1·20] | 1·16 [1·14–1·19] | 1·20 [1·17–1·22] |
Multiplier of the hazard ratio (interaction term in model) for the difference in speed of improvement between accredited and non-accredited centers.
EBMT risk score (score points 0–7 for allogeneic, 0–5 for autologous HSCT: age of patient: < 20 years = 0, 20–40 years = 1, > 40 = 2; disease stage: early = 0, intermediate = 1, advanced = 2; time interval from diagnosis to transplant: < 1 year = 0, > 1 year = 1; allogeneic HSCT only: donor type: HLA id sibling = 0; other donor = 1; donor recipient gender combination: all other = 0, female donor for male recipient = 1).